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Some strains of Neisseria gonorrhoeae are sensitive to the bactericidal action of fresh 
human  serum,  whereas  others  are  resistant.  The  majority  of N.  gonorrhoeae strains 
causing  disseminated  gonococcal  infection  (DGI) 1 are  resistant  to  the  bactericidal 
action  of fresh human  serum  (1-4).  Strains  causing DGI, however, appear to be a 
heterogeneous group.  Strains that give rise to tenosynovitis, skin lesions, and bacter- 
emia are more resistant  to normal human serum  (NHS) or autologous convalescent 
serum than strains causing suppurative arthritis  (5). 
The mechanisms of serum resistance in N. gonorrhoeae are incompletely understood. 
Two types of serum resistance have been identified:  stable and unstable  (6-8). The 
stable form of serum resistance persists even after prolonged culture of the bacteria on 
agar, whereas the unstable form is rapidly lost during passage on agar in the absence 
of serum.  Strains of N. gonorrhoeae causing DGI demonstrate stable serum resistance. 
Some studies have suggested that serum resistance in other gram-negative bacteria is 
related  to  the  presence  of blocking  antibody  in  human  serum  (9-12).  Moreover, 
antibody of the IgG class blocked killing of serum-resistant N. gonorrhoeae by rabbit 
serum  (13).  This  blocking  antibody  also  blocked  IgM-mediated  killing  of serum- 
sensitive as well as serum-resistant N. gonorrhoeae by NHS or human immune serum, 
respectively (14). 
Because the complement system is required  for serum killing of serum-sensitive N. 
gonorrhoeae, an understanding of the interaction between complement and N. gonorrhoeae 
may  clarify  the  mechanism  of serum-resistance.  Previous  reports  have  described 
decreases  in  hemolytic  activity  in  serum  incubated  with  resistant  N.  gonorrhoeae, 
suggesting either specific complement activation or nonspecific consumption (15,  16). 
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Studies of serum-resistant Salmonella  minnesota  have suggested that  resistance in this 
bacterium is related to failure of the complement membrane attack complex (MAC) 
to insert into hydrophobic domains of the outer membrane (17,  18).  We undertook 
the following studies to assess the interaction of the complement system with resistant 
and sensitive _IV.. gonorrhoeae to characterize the relationship of the complement system 
to serum resistance. 
Materials and Methods 
Serum.  Pooled NHS was prepared by centrifugation (2,000 g at 4°C) of freshly clotted blood 
(30-60 min at room temperature) obtained from three or more normal volunteers who had no 
history  of gonococcal  infection. This  pooled  NHS  was  used  in  all  experiments except  as 
indicated otherwise.  Heat-inactivated NHS (ANHS) was prepared by heating NHS at 56°C for 
30 min. 
Bacteria.  Serum-resistant strains (Willis and Davis) were isolated from blood or joint fluids 
of patients with DGI. One serum-sensitive  strain (N24) was obtained from the San Diego Public 
Health Laboratories and another (F62)  from Dr. Jerry  Brown  (Center for  Disease  Control, 
Atlanta, GA). Bacteria were maintained at -70°C in citrated rabbit blood until use. When 
needed, bacteria were  grown  on GC  agar  plates supplemented with  1%  IsoVitaleX  (BBL 
Microbiology Systems,  Becton, Dickinson & Co.,  Cockeysville,  MD) at 37°C in 5% COz and 
subcultured daily by selecting multiple colonies of typical T2 colonial morphology (19). For 
cloning experiments, single colonies were selected,  plated, and grown at 37°C in 5% CO2. 
Bactericidal Assays.  Gonococci grown 18-24 h were examined to ensure that >99% were T2 
colony type, suspended in Dulbecco's minimal essential media (MEM)  (Gibco Laboratories, 
Grand Island Biological Co., Grand Island, NY) by vigorous pipetting for uniform dispersion, 
and centrifuged (64 g) for 30 s to sediment agar and large clumps of bacteria. The suspension 
was adjusted by addition of MEM to an absorbance 610 nm (A610) corresponding to the desired 
concentration of bacteria. The correlation between A810 and bacterial concentration had been 
determined previously by plate counts. Equal amounts of Bacterial suspension and NHS or 
ANHS were mixed and incubated at  37°C in 5% CO2  for  1 h.  After incubation, bacterial 
viability was determined as previously described (20). The bactericidal capacity of NHS was 
expressed either as the difference between the number of colony-forming  units (CFU) surviving 
in ANHS and in NHS or, in the case of log10 killing, as the difference between the log~0 of the 
number of CFU in ANHS and in NHS. 
Complement Depletion Assays.  Suspensions of bacteria varying from  107/ml to  109/ml  were 
prepared in MEM, mixed with equal amounts of NHS, and incubated at 37°C in 5% CO2 for 
1 h. For determination of the amount of complement in serum not exposed to bacteria, equal 
amounts of NHS and MEM were  mixed and incubated. After incubation, an aliquot from 
each sample was removed for a bactericidal assay, and the remaining sample was centrifuged 
(15,000 g) for 10 min in a microfuge to pellet the bacteria. The supernatant was removed and 
used  for  complement determinations or  frozen  at  -70°C  if determinations were  not  done 
immediately. 
The total hemolytic activity (CHs0), C4 hemolytic activity, and C2 hemolytic activity were 
determined by standard procedures (21). C7 hemolytic activity was determined as follows. C7- 
depleted serum (C7d)  was prepared by affinity chromatography (22). A  1:20 dilution of the 
test  sample was prepared, and 2-20s/~1 aliquots were added to mixtures of 0.1  ml antibody- 
sensitized sheep erythrocytes (5 X 10/ml), 0.3 ml veronal-buffered saline with gelatin (GVB), 
and 0.02 ml C7d serum on ice and then incubated at 37°C for 30 min. After incubation, 1.0 ml 
cold  GVB  was  added,  each  mixture centrifuged  (500  g)  for  3  min,  and  the  A412 of  the 
supernatant determined. The C7 hemolytic activity expressed  as z/ml was calculated. 
Cls Activation Assay.  Activation of C ls was determined as previously described (23). In brief, 
purified Cls, kindly provided by Dr. Robert Ziccardi of Scripps Clinic and Research Founda- 
tion, was labeled with 125I (New England Nuclear, Boston, MA) by the solid-phase lactoper- 
oxidase method to a specific activity of 0.5 #Ci//~g.  12SI-Cls at 5% of the concentration of Cls 
in normal serum was added to NHS and equilibrated for 60 min at 37°C. Bacterial pellets were 
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(10,000 g) for 5 min and removing the supernatants. Next, 0.025 ml of NHS containing 125I-C  ls 
was added to the bacterial pellets,  vortexed vigorously to suspend the bacteria, and incubated 
at 37°C for 30 min. To assess spontaneous activation of Cls, 0.025 ml NHS containing 125I-Cls 
was added to 0.025 ml MEM in the absence of bacteria. Cls activation was also assessed by 
adding 0.25  ml NHS containing 125I-Cls to  100 #g human aggregated IgG  (HAGG).  (The 
HAGG was  prepared by heating the IgG [10 mg/ml] at 63°C for 20 min and centrifuging 
[10,000 g] for 3 min to remove large complexes.)  After incubation at 37°C for 30 min, EDTA 
(10 mM final concentration) was added to the mixtures, vortexed, allowed to stand for 5 min, 
and then the bacteria were pelleted. The ~2~I-Cls in the supernatant was analyzed by sodium 
dodecyl sulfate-polyacrylamide  gel electrophoresis (SDS-PAGE) in tube gels (3% stacking gel, 
7% separating gel) under reducing conditions according to Laemmli (24). The gels were cut 
into 1.5-ram segments, and each slice was counted in a gamma scintillation  spectrometer. Cls 
activation was determined as the fraction of total counts (in percent) migrating as activated 
125I-Cls. Specific  Cls activation was determined by subtracting the percent Cls activated in 
NHS incubated with MEM from the percent Cls activation produced by HAGG or bacteria 
samples. 
C5 Activation and Binding Assay.  C5 was purified as described (25) except as a  final step, 
affinity chromatography on concanavalin  A-Sepharose 4B was used, and then labeled with 1~5I 
incubated at 37°C in 5% COs for  1 h. Samples containing rabbit erythrocytes (ER) (1  ×  10  s) 
and zymosan (250/~g) were also prepared to assess C5 activation and binding in this assay. One 
set of the duplicate samples was then centrifuged (10,000 g)  for 5 rain, and aliquots of the 
supernatants and pellets were analyzed for le5I-C5 activation on a  SDS-PAGE slab gel  (3°7o 
stacking gel, 7% separating gel) under reducing conditions according to Laemmli (24). The gel 
was dried and an autoradiograph was prepared to assess conversion of C5 to C5b. The second 
set  of samples was  analyzed for  12SI-C5 binding to  the  bacteria by vortexing, layering the 
samples on top of 0.3  ml of 10%  (wt/vol) sucrose  in veronal-buffered saline with Ca  ++ and 
Mg  ++ (VB ++) containing  0.1 mg ovalbumin (Calbiochem-Behring  Corp., La Jolla, CA) per ml 
in 0.4 ml microfuge tubes, and centrifuging (10,000 g) for 3 rain. The supernatants and pellets 
were  separated by removing the bottoms of the tubes with a razor blade and counting in a 
gamma scintillation spectrometer. Molecules of C5 bound per cell were determined as follows. 
Molecules of C5  in the  NHS  containing a25I-C5 were  calculated  based  on  normal serum 
concentration of C5  (70/zg/ml). The functional activity of a25I-C5 used was estimated to be 
33%  based on maximum incorporation of 125I-C5 into SC5b-9 in NHS  upon activation by 
zymosan (10 mg/ml) (27). The amount of x25I-C5 bound was corrected for functional activity 
of ~25I-C5 to calculate total C5 binding. Finally, the total C5 bound was divided by the number 
of bacteria (109) in the assay. 
Specific  binding of x25I-C5 to  the  bacteria  was  determined according  to  the  following 
formula: 
pellet (NHS)  cpm pellet (&NHS)~ 
percent specific binding ---- \  cpm total (NHS)  cpm total (&---'N-~f  ×  100. 
t~I-C5 and 1aII-C9 Binding Assay.  Purified C5 and C9 (28) were prepared and differentially 
labeled with 125I and aalI (ICN Nutritional Biochemicals, Cleveland, OH) respectively, by the 
iodogen method. The specific  activity of la1I-C9 was  0.4/~Ci//~. Freshly centrifuged 131I-C9 
(10,000 g for 5 min) was added to NHS and ANHS to give 2 X 10  cpm/ml serum. The specific 
activity of a25I-C5 and  amount added  to  NHS  and  ANHS  were  as  described  for  the  C5 
activation and binding  assay. To bacterial pellets containing l0  s bacteria prepared in microfuge 
tubes as  described above, increasing amounts of NHS  containing a25I-C5 and  laxI-C9 were 
added. The mixtures were vortexed and incubated at 37°C in 5% CO~ for 1 h. ANHS (0.5 ml) 
containing ~25I-C5 and laaI-C9 was  incubated with bacterial pellets to determine nonspecific 
binding. After incubation, MEM was added as necessary to a final volume of 0.5 ml. An aliquot 
(0.1 ml) was removed from each tube and layered on 0.3 ml of 10% (wt/vol) sucrose  in VB ++ 1238  COMPLEMENT  ACTIVATION  BY  SERUM-RESISTANT  N.  GONORRHOEAE 
containing 1.0 mg ovalbumin/ml in a 0.4 ml microfllge tube. The tubes were then centrifuged, 
after which supernatants and pellets were separated and counted for both 125I-C5 and 131I-C9. 
The 125I counts were corrected for crossover from 131I. The molecules of C5 and C9 bound per 
cell were  calculated  as  described  above.  Calculations  were  based  on  33%  131I-C9  functional 
activity. The C9/C5 ratio was calculated from the molecules per cell data. 
Assay of SC5b-9 Formation.  Aliquots of the supernatants obtained from the C5 activation and 
binding assay were layered on top of a 4.5-ml  10%-40% sucrose gradient in VB  ++ with a 0.5 ml 
66%  sucrose  cushion.  The  samples  were  centrifuged  in  a  Beckman  ultracentrifuge  (L5-65; 
Beckman Instruments, Inc., Fullerton, CA) with a  SW50.1  rotor at 36,000 rpm, 4°C  for  16 h. 
The samples were then fractionated and counted in a gamma scintillation spectrometer for 125I- 
C5. The location of radiolabeled SC5b-9 within the gradient was determined from zymosan- 
treated samples, and the percent of 125I-C5 incorporated into SC5b-9 was calculated. 
Electron Microscopy.  Bacteria were incubated with MEM,  NHS,  or ANHS  as described for 
the bactericidal assays.  After incubation, they were centrifuged  (10,000 g)  for 5  rain, washed 
twice with 0.2 ml of 0.5  M  phosphate buffer (pH  8.0),  and resuspended in 0.2 ml VB  ++. To 
each sample,  20/~g of trypsin and  20/~g of chymotrypsin  (Worthington Biochemical  Corp., 
Freehold, N J) were added before overnight incubation at room temperature. The samples were 
then washed  twice in 0.2  ml VB  ++  and resuspended  in 0.05  ml VB  ++,  after which  5  ~1 was 
placed  on  parlodion  and  carbon-coated  400-mesh  copper  grids,  stained  with  1-2%  uranyl 
formate,  and examined in a  Hitachi  12A electron microscope operated at  75 kv accelerating 
voltage and a  direct magnification of 40,000. 
Results 
Effect of NHS on Serum-resistant  and Serum-sensitive  N.  gonorrhoeae.  To  determine the 
bactericidal capacity of NHS against resistant and sensitive N. gonorrhoeae, we deter- 
mined  the  bacteria  surviving  as  CFU  when  increasing  numbers  of bacteria  were 
added to a  constant volume of NHS.  Fig.  1 shows that essentially all bacteria of the 
serum-sensitive strain N24 were killed when  107 CFU were added to  1 ml of NHS. As 
the concentration of N24 incubated with NHS was  increased, more bacteria (CFU) 
were killed, but a  smaller percentage of the total number was killed (decreasing log10 
killed). In contrast, there was no significant killing (<0.1  log) of the serum-resistant 
strain Willis at bacterial concentrations of 107-108/ml. 
Because subsequent experiments (see below) showed that complement was activated 
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Fie.  1.  Killing of serum-resistant and -sensitive N. gonorrhoeae  by NHS. The numbers of CFU killed 
(  ) and log10 CFU killed (  .....  ) by NHS are shown for a serum-resistant strain, Willis ([~), and 
a serum-sensitive strain, N24 (©) as increasing numbers of CFU were incubated with 1 ml of NHS. HARRIMAN,  PODACK, BRAUDE, CORBEIL, ESSER, AND CURD  1239 
by serum-resistant N.  gonorrhoeae, it became important to determine if any resistant 
bacteria could be killed by NHS.  Because our standard bactericidal assay does not 
detect killing of small numbers of bacteria when high bacterial concentrations (I0S/ 
ml)  are used,  additional experiments in which  104 bacteria/ml had  been added  to 
NHS were performed. Results of five identical experiments showed that the decrease 
in CFU incubated in NHS compared with ANHS was 29%  -+  17%  for the resistant 
Willis strain and 19% +  21% for the resistant Davis strain. To exclude the possibility 
that a subpopulation of relatively serum-sensitive  clones existed within the population 
of the serum-resistant strain, 10 separate clones of Willis were also tested in bactericidal 
assays at  a  concentration of I0  s  bacteria/ml of NHS.  None of the clones exhibited 
more than a 0.2 log decrease in the number of CFU in NHS compared with ANHS. 
Depletion  of Complement  Components.  In a  series of experiments, the CH50,  C4, C2, 
and C 7 activities were determined in NHS after incubation  with resistant and sensitive 
N. gonorrhoeae (Table I). The serum-resistant strain Willis depleted 25% of the CH~0 
activity and 33% of the C2 activity in NHS. The two serum-sensitive strains F62 and 
N24 depleted ~33% of the CHso activity and 50% of the C2 activity in NHS. Neither 
C4 nor C7 activity was depleted in detectable amounts by either resistant or sensitive 
TABLE  I 
Complement Component Activity Remaining in NHS Incubated with Resistant and Sensitive N. Gonorrhoeae 
Concen- 
tration  Bacterial  CHso (three  C4 (one  C2 (two  C7 (one 
orga-  experiments)  experiment)  experiments)  experiment)  strain  nisms/ 
ml 
z/ml  z/ml  z/ml 
No bacteria  0  77 ±  10.6  20,960 + 2,028  116 +  16.8  4,306 ± 442 
Willis  10  s  58 ± 4.9 (25%)*  19,418  78 ± 20.6 (33%)  4,398 
F62  l0  s  52 ± 4.7 (32%)  18,182  60 ± 24.2 (48%)  4,186 
N24  10  s  51 ±  10.0 (34%)  21,200  60 ± 23.6 (48%)  4,258 
* Numbers in parentheses are percent decrease compared to controls with no bacteria. 
TABLE II 
Total Hemolytic Activity (CHso) Remaining in NHS after Incubation with 
Resistant and Sensitive N. gonorrhoeae 
Concentration  Percent decrease  Bacterial strain  CH~0 units  organisms/ml  (CH~o) 
No bacteria  0  63.4 + 7.2  0 
Willis  107  46  27 
10  a  42  33 
109  <28  >55 
Davis  107  52  18 
10  a  44  30 
109  <28  >55 
F62  107  47  25 
lO  s  40  37 
10  9  <28  >55 
N24  10  7  48  25 
lO  s  38  40 
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TABLr  III 
Activation of ¢25I-Cls in NHS by Resistant  and Sensitive N. gonorrhoeae 
Assay constituents 
Percent ~25I-C  Is Conversion 
10  s Bacteria  109 Bacteria 
HAGG +  0.025  ml ~2~I-Cls  36.3  23.7 
Willis +  0.025 ml 12~I-Cls  0*  21.4 
Davis +  0.025 ml ~25I-Cls  0*  19.0 
F62 +  0.025 ml ~25I-Cls  0*  18.1 
N24 +  0.025 ml 125I-C1s  0*  32.3 
* No measurable conversion. 
Fie.  2.  (Left)  SDS-PAGE tube gel analysis of 12sI-Cls activation in NHS incubated with serum- 
resistant and -sensitive N. gonorrhoeae.  Positions of the unactivated heavy chain of 125I-C  ls (C is) and 
the activated (cleaved)  heavy chain of 12~I-C 1  s (C ls-) are indicated in the upper left panel. Activation 
of 125I-Cls in NHS by buffer, HAGG, serum-resistant (Davis)  and -sensitive (N24)  N. gonorrhoeae  is 
shown. 
FIG.  3.  (Right)  Autoradiogram of an  SDS-PAGE  slab  gel  demonstrating I~5I-C5 activation in 
NHS  by serum-resistant and -sensitive N. gonorrhoeae. The positions of the C5a,  CSa',  and C5fl 
chains of C5 are indicated by arrows. The following samples were applied to the SDS-PAGE slab 
gel: (1) supernatant from ANHS containing.  .  a25125I'C5,  incubated with a serum-resistant strata" (Willis); 
(2)  supernatant  from  NHS  containing  I-C5  incubated with  Willis;  (3)  bacterial  pellet  from 
incubation of Willis in  NHS  containing 125I-C5; (4)  supernatant  from  NHS  containing 125I-C5 
incubated with a serum-sensitive strain (N24);  (5) bacterial pellet from incubation of N24 in NHS 
containing 125I-C5. 
strains when  108 bacteria were incubated  with  1 ml of NHS. 
To  evaluate  the  dose-response  relationships between  the  number  of bacteria  incu- 
bated  in  NHS  and  consumption  of  complement,  different  amounts  (107-109)  of 
bacteria were added  to  1 ml of NHS.  As seen in Table  II, both  serum-resistant strains 
(Willis and  Davis)  and  -sensitive strains (F62 and  N24)  depleted comparable  amounts 
of complement.  In addition, the CHs0 depletion increased in all cases as more bacteria 
were added  to NHS. 
Activation of C1.  To  evaluate activation of the classical pathway,  10  s bacteria were 
incubated  with 0.025 ml of NHS  containing  a25I-C 1  s. No C 1  s activation was detectable 
with either resistant or sensitive strains  (Table III).  However,  when  109 bacteria  were 
added  to 0.025 ml of NHS  containing  125I-C ls, both resistant strains, Willis and Davis, HARRIMAN,  PODACK,  BRAUDE,  CORBEIL,  ESSER,  AND  CURD  1241 
TABLE IV 
Binding of t~I-C5 in NHS to Resistant and Sensitive N. gonorrhoeae 
Molecules C5  Percent ~esI-  Percent spe-  Assay constituents*  per cell:~  C5 binding  cific binding 
En +  0.05 ml NHS  48,000  15.2  14.3 
ER +  0.05 ml ANHS  2,800  0.9 
Willis +  0.05 ml NHS  3,700  11.6  8.0 
Willis +  0.05 ml ANHS  1,100  3.6 
Willis +  0.2 ml NHS  9,500  7.5  6.2 
Willis +  0.2 ml ANHS  1,600  1.3 
N24 +  0.05 ml NHS  3,350  10.6  8.8 
N24 +  0.05 ml ANHS  600  1.8 
N24 +  0.2 ml NHS  9,500  7.5  6.2 
N24 +  0.2 ml ANHS  1,600  1.3 
* The amounts of ER and AT.. gonorrhoeae used in these assays were 1 ×  10  s and 
1 ×  10  9 per assay, respectively. 
:~ For calculations of estimated molecules per cell see Materials and Methods. 
TABLE  V 
Binding of 1251-C5 and t311-C9 in NHS to Resistant and Sensitive N. gonorrhoeae 
Molecules per cell~  Percent binding  C9/C5 
Assay constituents* 
C5  C9  125I_C5  131I_C9  Ratio§ 
Willis +  0.05 ml NHS  24,000  127,000  7.7  18.5  5.2 
Willis +  0.1 ml NHS  48,000  337,000  7.6  24.6  7.0 
Willis +  0.25 ml NHS  100,000  818,000  6.3  23.9  8.2 
Willis +  0.5 ml NHS  186,000  1,241,000  5.9  18.1  6.7 
Willis +  0.5 ml ANHS  28,000  59,000  0.9  0.9  2.1 
N24 +  0.05 ml NHS  16,000  96,000  5.0  14.0  6.1 
N24 +  0.2 ml NHS  30,000  154,000  4.7  11.2  5.2 
N24 +  0.25 ml NHS  61,000  418,000  3.8  12.2  6.8 
N24 +  0.5 ml NHS  129,000  757,000  4. l  11.0  5.6 
N24 +  0.5 ml ANHS  58,000  94,000  1.8  1.4  1.6 
* The amounts ofN. gonorrhoeae used in these assays were 1 X  l0  s per 
For calculations of molecules per cell see Materials and Methods. 
§ For calculations of C9/C5 ratio see Materials and Methods. 
assay. 
as  well  as  one  sensitive  strain,  F62,  activated  ~20%  of the  Cls,  whereas  the  other 
sensitive strain, N24,  activated  a  little more  than  30% of the Cls  (Table III, Fig.  2). 
Activation  and Binding  of C5.  When  NHS  containing  125I-C5  was  incubated  with 
resistant and  sensitive strains, both  strains activated  C5  as shown  by the presence of 
C5a'  in  the pellets  (Fig.  3).  Bacteria  incubated  with  ANHS  did  not  activate  C5.  In 
addition  to  activating  C5,  both  resistant  and  sensitive  strains  bound  comparable 
amounts  of 125I-C5  to their surfaces at  the end of 1 h  incubation  in NHS  (Table IV). 
Far less C5  bound  to the bacteria  in ANHS  than  in NHS.  Specific binding  was 8.0% 
for  Willis  and  8.8%  for  N24  after  incubation  with  0.05  ml  NHS.  When  a  larger 
volume  of NHS  (0.2  ml)  containing  leaI-C5  was  incubated  with  the  bacteria,  more 
molecules of C5 were bound  to the bacteria, but  once again  the amounts  bound  were 1242  COMPLEMENT  ACTIVATION BY  SERUM-RESISTANT  ~  GONORRHOEAE 
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Fro.  4.  Sucrose density gradient  ultracentrifugation analysis of SC5b-9  formation in  NHS con- 
taining 125I-C5 incubated with serum-resistant and -sensitive N, gonorrhoeae. The sedimentation of 
12SI-C5 (C5)  and  lzSI-SC5b-9  (SC5b-9)  in  the  sucrose  density  gradient  is  indicated  by  arrows. 
Incorporation of azsI-C5 in SC5b-9 is shown for ANHS incubated with zymosan, and NHS incubated 
with zymosan, serum-resistant strain Willis,  or sensitive strain N24. 
similar  for  both  resistant  and  sensitive  strains.  Nonspecific  binding  in  this  larger 
amount  of ANHS was equal for both strains (1.3%)  as was specific binding (6.2%). 
125I-C5 and 131t-C9 Binding to Resistant and Sensitive N. gonorrhoeae.  The simultaneous 
binding of lz5I-C5 and talI-C9 was  measured to assess formation of the MAC on  the 
bacterial  surfaces.  Both  the  resistant  strain  Willis  and  the  sensitive  strain  N24 
specifically bound  radiolabeled  C5  and  C9  (Table  V).  In  these  experiments,  l0  s 
bacteria were incubated with increasing amounts of NHS  to which radiolabeled C5 
and C9 had been added. The number of C5 and C9 molecules bound to both resistant 
and sensitive strains increased as the bacteria were incubated with increasing amounts 
of NHS.  The  binding of C9  to  the bacteria was  greater  than  that  of C5  at  higher 
serum  concentration,  resulting in  a  C9/C5  ratio with  a  maximum  of 8.2  for Willis 
and  6.8  for  N24.  The  nonspecific binding of 12SI-C5  and  131I-C9  to  both  strains  in 
ANHS was very low compared with binding in NHS, and the ratio of C9/C5  bound 
to the bacteria in ANHS was much lower than in NHS. 
12~I-C5 and la1I-C9 Binding to Resistant and Sensitive AT. gonorrhoeae.  The simultaneous 
binding of lz5I-C5 and  t3II-C9 was measured  to assess formation of the MAC on the 
bacterial  surfaces.  Both  the  resistant  strain  Willis  and  the  sensitive  strain  N24 
specifically bound  radiolabeled  C5  and  C9  (Table  V).  In  these  experiments,  l0  s 
bacteria were incubated with  increasing amounts of NHS to which radiolabeled C5 
and C9 had been added. The number of C5 and C9 molecules bound to both resistant 
and sensitive strains increased as the bacteria were incubated with increasing amounts 
of NHS.  The  binding of C9  to  the  bacteria was  greater than  that  of C5  at  higher 
serum  concentration,  resulting in  a  C9/C5  ratio with  a  maximum  of 8.2  for Willis 
Fro.  5.  MAC  formation  on  the  surfaces  of  serum-resistant  (Willis)  and  -sensitive  (N24)  N. 
gonorrhoeae.  Electron  micrographs of sensitive strain  N24  incubated  in  buffer  (A),  in  NItS  (B), 
resistant strain Willis in NHS  (C),  fused membrane vesicles  from Willis in NHS (D), and  N24  in 
NHS  (E and F).  Arrows in panel C  denote membrane blebs on surface of Willis and  arrowheads 
indicate  MAC.  In panel  D, fused membrane vesicles  from Willis contain  MAC  (arrowheads). In 
panels E  and  F, arrows point to membrane blebbing on surface of N24 and arrowheads point  to 
MAC. Bar =  lO0 nm. HARRIMAN,  PODACK, BRAUDE, CORBEIL,  ESSER, AND CURD  1243 1244  COMPLEMENT  ACTIVATION BY  SERUM-RESISTANT N~  GONORRHOEAE 
Fie. 6.  Identification of bacterial surface structures and MAC on N. gonorrhoeae. Panel A demon- 
strates ring-like structures on surface of serum-sensitive bacteria (inner diameter, 8 nm) not exposed 
to NHS (arrow). Panel B shows serum-sensitive strain (N24) incubated with NHS. In panel B MAC 
are seen on bacterial surface in two views, from above (arrow) and side view (double arrowheads) 
(inner diameter of MAC, 11 nm). Bar =  100 nm. 
and  6.8  for  N24.  The  nonspecific binding of 125I-C5  and  la1I-C9  to  both  strains  in 
ANHS was very low compared with binding in NHS, and the ratio of C9/C5  bound 
to the bacteria in ANHS was much lower than in NHS. 
SC5b-9  Formation by Resistant and Sensitive N. gonorrhoeae.  NHS  containing  lz5I-C5 
was  incubated  with  bacteria,  and  then  the  radioactivity  in  the  supernatant  was 
ana[yzed by sucrose density gradient ultracentrifugation. Small amounts of 125I-C5  in 
NHS  incubated  with  either resistant  or  sensitive bacteria sedimented  in  a  position 
identical to  that  of SC5b-9  formed upon  treatment  of NHS  with  zymosan  (Fig. 4). 
The  amount  of 125I-C5  at  this  position in  NHS  incubated  with  the  resistant  strain 
Willis varied from  10.9% to  16.7% of the total azSI-C5 in the supernatant, whereas the 
sensitive strain N24 had  11.5%-11.9%  125I-C5  at this position. 
Electron Microscopy of Resistant  and  Sensitive N.  gonorrhoeae.  After  incubation  with 
NHS,  both  resistant  and  sensitive strains  of N.  gonorrhoeae had  typical complement 
lesions on their surfaces (Figs. 5  and 6).  In addition to complement  lesions, ring-like 
structures (inner diameter, 8  nm) can be seen on the surface of the bacteria incubated 
in NHS or ANHS (Fig. 5 B). In contrast to the MAC, these complement-independent 
ring structures do not extend above the surface of the bacterial membrane  as do the 
MAC  (Fig. 6 B).  Serum-resistant strains exhibited the same 8-rim  ring structures  on 
their  surface  (not  shown).  After  incubation  with  NHS,  the  serum-resistant  strain 
Willis and -sensitive strain N24 both had numerous MAC deposited on their surface 
(Fig.  5C-F),  which  were  clearly  distinguishable  from  the  8-nm  ring  structures. 
Another prominent feature was the blebbing of the outer membrane of both resistant 
and  sensitive bacteria.  In  some  cases,  fused  membrane  blebs,  with  MAC  on  their 
surface,  could  be  seen  (Fig.  5 D).  This  blebbing  phenomenon  appeared  somewhat 
more prominent in the resistant strain. HARRIMAN, PODACK, BRAUDE, CORBEIL, ESSER, AND CURD  1245 
Discussion 
Our new finding regarding the interaction of human complement with N. gonorrhoeae 
is that  the classical pathway of complement is specifically activated by resistant  as 
well as sensitive N. gonorrhoeae. Complement activation by both types of bacteria is 
qualitatively  and  quantitatively  similar  and  leads  to  MAC  formation  and  stable 
deposition on the surface of both resistant and sensitive N. gonorrhoeae. 
More  specifically, we  found  that  essentially  100%  of the  organisms of a  serum- 
sensitive strain, N24, were killed in NHS at concentrations  that did not completely 
deplete the complement in NHS. With higher concentrations of organisms, the log10 
killed  diminished  significantly.  This  probably  occurred  because  the  bactericidal 
capacity of NHS was approached at the highest concentration of bacteria, as evidenced 
by loss of measurable CHs0 activity in NHS incubated with  109 bacteria/ml. There 
was a  clear dose-response relationship  between  the initial  number of bacteria incu- 
bated with NHS and the number of sensitive bacteria killed, as well as the amount of 
CHs0 activity depleted by both resistant and sensitive bacteria. 
Although resistant strains at various concentrations consumed comparable CHs0 to 
that of sensitive strains, they were not killed. At low concentrations (104/ml), a few of 
the  resistant  bacteria  (20%-30%)  seemed  to  be  killed;  however,  because  of errors 
inherent  in the bactericidal assay and certain characteristics of the gonococcus (e.g., 
clumping),  it  is  difficult  to  assess  small  amounts  of killing.  For  these  reasons,  a 
significant  amount  of killing  is usually  defined  as >1  log  (29).  If, in  fact,  a  small 
percent of resistant bacteria are killed by NHS, the cause is not a  sensitive subpopu- 
lation, as shown by our cloning experiments. In addition,  the killing of such a  small 
percentage of bacteria would be unlikely to account for comparable amounts of CHs0 
depletion by resistant and sensitive N. gonorrhoeae. 
Stable serum resistance in N. gonorrhoeae does not result  from lack of complement 
activation.  Resistant as well as sensitive strains activate C ls and consume C2. Thus, 
both strains can activate the classical pathway.  Because C2  represents  the  limiting 
component  of the  classical  pathway,  the  decreased  CH~0  probably  represents  C2 
depletion, whereas the absence of detectable C4 or C7 depletion indicates the relative 
excess of these components in serum. The large number of bacteria required to detect 
C ls activation is also consistent with the presence of an excess of C 1 relative to C2 in 
serum. 
The activation of C5 in NHS by both resistant and sensitive bacteria demonstrates 
that a C5 convertase had formed. After activation, C5b is bound to both resistant and 
sensitive strains as shown by equal deposition of C5b at the end of a  1-h incubation. 
As the amount of serum added was increased, additional molecules of C5b bound. C9 
was also shown  to remain bound  to both resistant  and  sensitive bacteria.  Previous 
reports have suggested that  the ratio of C9 molecules to C5 molecules incorporated 
into the MAC, as measured by radiolabeled components, is -->6:1. The ratio of C9/C5 
bound to both resistant and sensitive strains in these experiments suggests that these 
components were incorporated into the MAC. Although some SC5b-9 was formed by 
both resistant and sensitive bacteria, there was no marked difference in the amount 
formed by either strain. 
Both resistant and sensitive strains had MAC deposited on their surfaces as seen in 
the  electron  microscope.  Also  apparent  were  inherent  ring-like  structures  clearly 
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for the gonococcus (30) and meningococcus (31). Another notable feature was blebbing 
of  the  membrane  with  release  of  vesicles  from  bacterial  membranes.  Although 
blebbing appeared somewhat more prominent  in  the  resistant  bacteria than  in  the 
sensitive strain,  the significance is uncertain.  Blebbing of membranes has also been 
reported previously for the gonococcus (32). 
Previous studies of serum-resistant  and sensitive S.  minnesota  showed that both the 
resistant  and  sensitive  strain  activated  complement  (15,  16). After  complement 
activation, C5b-7 bound stably to the resistant Salmonella strain, but upon the addition 
of C8 and C9, the C5b-7 disassociated from the bacteria in the form of SC5b-9. This 
dissociation  did  not  occur in  the  sensitive  strain,  rather  the  terminal  components 
remained  bound  to  the  bacteria,  presumably  in  the  form  of the  MAC,  and  were 
capable of killing the bacteria. 
The  interactions  of  complement  with  resistant  strains  of  S.  minnesota  and  N. 
gonorrhoeae  differ  in  several  respects,  suggesting  different  mechanisms  of resistance. 
Although both activate the complement system, resistant S.  minnesota  consumes more 
terminal complement components than the sensitive strain (15,  16), whereas resistant 
N. gonorrhoeae does not. Unlike resistant  S.  minnesota,  the resistant  N. gonorrhoeae have 
C5 and C9 bound to their surfaces at the end of 1 h of incubation, and the amounts 
of bound C5  and  C9  are  approximately equal  to  that  of the  sensitive  strain.  The 
ratios of C9/C5 bound to resistant  and sensitive  N. gonorrhoeae are comparable, 'and 
suggest  that  C5  and  C9  are  incorporated into  MAC,  unlike  the  decreased  C9/C5 
ratios observed on resistant S.  minnesota  (15,  16). The amounts of SC5b-9 formed by 
both resistant and sensitive N. gonorrhoeae are also comparable, indicating no difference 
in release of terminal component complexes from bacterial surfaces. Finally, electron 
microscopy  revealed  MAC  bound  to  both  resistant  and  sensitive  N.  gonorrhoeae. 
Therefore, MAC is formed and remains on the surfaces of both resistant and sensitive 
N. gonorrhoeae after activation of complement. 
Although MAC is formed and remains on the surface of resistant N. gonorrhoeae, the 
precise location of the MAC in the membrane is unknown. Our electron microscopy 
studies suggest that MAC becomes inserted in the outer membranes of some resistant 
bacteria, but the possible relationship  between MAC location and viability remains 
to be determined. Possibly, a critical region on the bacterial surface determines killing. 
Complement-mediated killing of Escherichia coli has been shown to occur with simul- 
taneous release of markers from periplasmic and intracellular  spaces  (33,  34).  Some 
studies suggest the existence of regions in E.  coli  where inner and outer membranes 
join to form adhesion zones (35).  It is possible that MAC must insert at these critical 
regions of the bacterial surface to effect killing. Blocking antibodies are known to play 
a  role  in  AT.  gonorrhoeae  serum  resistance,  and  blocking  antibody  may prevent  the 
insertion of MAC at these critical regions. 
The precise events at a  molecular level  that determine serum-resistance in certain 
N. gonorrhoeae remain to be determined. Regardless of  what the mechanism of resistance 
is,  it will have to take account of the fact that serum-resistant iV. gonorrhoeae activate 
complement and bind MAC. 
Summary 
Interaction of the human complement system in normal human serum (NHS) with 
serum-resistant and -sensitive Neisseria gonorrhoeae was evaluated to better understand HARRIMAN, PODACK, BRAUDE,  CORBEIL,  ESSER,  AND CURD  1247 
the mechanism  of serum-resistance. Complement  activity (CHs0)  was depleted from 
NHS in a dose-dependent fashion by both serum-resistant and -sensitive N. gonorrhoeae. 
No  detectable  CHs0  remained  in  NHS  incubated  with  109  colony-forming  units 
(CFU)/ml  serum  of either  resistant  or  sensitive strains.  When  smaller numbers  of 
bacteria were  incubated  with  NHS,  lesser, yet comparable,  amounts  of CHs0  were 
depleted by both resistant and sensitive strains. Hemolytic C2 activity was diminished 
by 33% in the case of resistant N. gonorrhoeae  (10  s CFU/ml  serum)  and by 48% in the 
case of a  sensitive strain.  No  detectable decreases  in  hemolytic C4  or C7  activities 
were found with either sensitive or resistant strains at this concentration. 
Both resistant and sensitive strains activated C ls in NHS.  Resistant strains specif- 
ically activated 19-21% ofradiolabeled C ls in NHS, whereas sensitive strains activated 
18-32%.  Both resistant and sensitive strains also activated C5 in NHS. 
In  binding assays using radiolabeled C5  and  C9  in  NHS,  resistant  and  sensitive 
strains bound comparable amounts of C5 and C9. The number of bound C5 and C9 
molecules varied according to the number of bacteria or amount of serum used in the 
assay. The ratio of C9/C5 bound to a sensitive strain was 6.8, and to a resistant strain 
was  8.2,  suggesting  that  C5  and  C9  were  incorporated  into  membrane  attack 
complexes (MAC). Electron microscopic examination of resistant and sensitive strains 
incubated  with  NHS  revealed that  MAC  is bound  to  the surfaces  of the  resistant 
strain as well as the sensitive strain. 
Received  for publication 27 May 1982. 
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